Issue No. 3 · Week of August 31, 2026
Health Canada had a busy week of its own, flagging a sterile barrier failure at Maquet and a software gap at GE’s CARESCAPE monitors within a day of each other, while FDA escalated the Medline and B. Braun kit recall after a single recalled component drove 35 injuries. Both regulators are treating packaging validation and supplier traceability with the same weight as hardware defects.
On the trade side, Canada’s confirmed September 8 retaliation list still leaves medical devices off, which is worth banking as good news while it lasts.
Hospitals and Health Systems
New York health panel advances plan to fold Maimonides into NYC’s public hospital system
New York’s Public Health and Health Planning Council advanced a plan to bring Brooklyn’s Maimonides Health under NYC Health and Hospitals through new public subsidiaries, backed by a 2.2 billion dollar state grant, with a full council vote set for September 17. For a foreign manufacturer, folding a major Brooklyn hospital into the city’s public system would move purchasing decisions toward NYC Health and Hospitals’ centralized contracting.
Source: VINnews – August 27, 2026
Regulatory: FDA and Health Canada
Medline and B. Braun kits escalated to Class I recall over recalled bupivacaine component
FDA escalated the Medline convenience kit correction, tied to a recalled Huons bupivacaine injectable, to a Class I recall after B. Braun reported 35 serious injuries linked to the affected kits. It shows how a single foreign sourced component recall can escalate even after a manufacturer has already issued a correction, and how traceability obligations can tighten quickly once new injury reports come in.
Source: American Hospital Association – August 21, 2026
FDA opens comment period on how CDRH collects misconduct allegations against device firms
FDA is taking comment through October 26 on its process for collecting allegations of regulatory misconduct, which CDRH estimates receives roughly 2,800 reports a year covering issues like unregistered devices and quality system failures. It is a reminder that a formal, low barrier complaint channel exists, filed by anyone including a competitor or former employee, and regularly feeds FDA’s enforcement targeting.
Source: Federal Register – August 27, 2026
J&J’s Abiomed recalls Impella heart pump controllers after 3 deaths, 37 injuries
Johnson and Johnson’s Abiomed division recalled automated Impella heart pump controllers after FDA linked a purge pressure sensor defect, affecting about 0.2 percent of devices, to 3 deaths and 37 serious injuries. It is the latest in a run of quality problems at Abiomed since J&J’s 2022 acquisition, a reminder that recurring quality issues on one device line can draw sustained FDA scrutiny of a manufacturer’s broader quality system.
Source: MedTech Dive – August 28, 2026
Health Canada flags sterile barrier failure in Maquet percutaneous insertion kits
Health Canada issued a Type II recall for Maquet Cardiopulmonary’s PIK 150 and PIK Dilator Set L kits after the German manufacturer found, during a review of historical packaging data, that sterile barrier integrity testing had failed for some units still within shelf life. It is a reminder that a packaging validation gap found well after a product first ships can still trigger a formal recall months later, an exposure any foreign manufacturer selling sterile devices into Canada should keep in mind.
Source: Health Canada – August 26, 2026
GE’s CARESCAPE Central Station recalled in Canada over monitoring gap after restart
Health Canada classified a Type II recall of GE Medical Systems’ CARESCAPE Central Station patient monitoring hubs after finding the system can take at least three minutes to resume monitoring following a restart, creating a gap in bedside surveillance. It shows that a software or firmware level behavior, not only a hardware defect, can be enough to draw a formal device recall in Canada.
Source: Health Canada – August 26, 2026
Import, Customs and Trade
Canada publishes final counter tariff list; medical devices left off
Canada’s Department of Finance published its confirmed list of US goods facing 15, 25, and 50 percent retaliatory tariffs worth 27.6 billion dollars starting September 8, covering steel, dairy, appliances, agricultural equipment, pulp and paper, and electronics. Medical devices and instruments do not appear on the list, a reassuring detail for now, though the categories in this dispute have already shifted more than once.
Also Noted
Boston Scientific cyberattack disrupts customer orders
Boston Scientific disclosed a cyberattack that has disrupted its ability to process and ship customer orders, the latest in a run of attacks on device manufacturers this year.
Source: Becker’s Hospital Review
China state sponsored hacking group targeted U.S. hospitals
The FBI and DOJ seized domains tied to QTFY, a China state sponsored hacking group accused of breaching US hospitals since 2018 by exploiting unpatched VPN vulnerabilities.
Source: Becker’s Hospital Review
Key Takeaways for Medical Device Manufacturers
This week’s developments reinforce the importance of supplier traceability, packaging validation and software performance across both U.S. and Canadian regulatory systems. A problem originating with a single component can escalate into broader recalls, while packaging and software issues can trigger formal regulatory action even when the underlying device hardware is unaffected.
Manufacturers selling into Canada also received some positive trade news, with medical devices and instruments remaining off the country’s confirmed September 8 counter tariff list.
Questions About U.S. or Canadian Market Access?
Dawa Medical supports foreign medical device manufacturers entering the U.S. market as U.S. Agent, FDA Initial Importer and Importer of Record, with 3PL warehousing and regulatory compliance support. Through TB Medical Inc., manufacturers can also access Canadian importation and distribution support.
About The Access Brief: The Access Brief summarizes publicly reported news affecting medical device manufacturers selling into the United States and Canada and reflects Dawa Medical’s own understanding. It is not legal, regulatory or binding advice, and formal advice should come from qualified counsel or a specialist consultant.
